Arcturus Therapeutics Holdings Inc. (ARCT): R&D Expense
$112.21M
Year ended 2025-12-31
$86.78M
Trailing 12 months to 2026-06-30
-8.8%
3-year compound annual growth
+14.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $112.21M | -42.5% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $195.16M | +1.6% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $192.13M | +30.0% | 2026-03-03, From 2023-01-01 |
| 2022-12-31 | $147.75M | -15.0% | 2025-03-06, From 2022-01-01 |
| 2021-12-31 | $173.76M | +200.4% | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | $57.85M | +72.0% | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | $33.64M | +98.1% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $16.98M | n/a | 2021-03-01, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $112.21M | -42.5% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $104.00M | -5.1% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $316.90M | +43.0% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $7.76M | +138.6% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $13.18M | -32.7% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $25.99M | -9.9% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $416.03M | +22.6% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $68.73M | -17.6% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $186.83M | +11.7% |
Compare ARCT, ADCT, NRIX, ETON side by side · Screen every company in Pharmaceutical Preparations ↗